Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with Hig... (atients in this group could receive all ...)

HOME >> MEDICINE >> TECHNOLOGY

Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL

Date:12/9/2008

atients in this group could receive all six of the intended courses compared with an historic high-risk group treated with FCR. There was no significant difference in incidence of infection during treatment with CFAR compared to FCR, with the exception of cytomegalovirus (CMV) reactivation. Follow-up continues for the patients treated on this trial to evaluate responses in all 60 enrolled patients and time-to-event endpoints.

Abstract #329

Subcutaneous Alemtuzumab (Campath) in Fludarabine-Refractory CLL: Final Results of the CLL2H Trial of the GCLLSG and Comprehensive Analysis of Prognostic Markers

The multicenter trial evaluated subcutaneous alemtuzumab given three times weekly at 30 mg in fludarabine refractory CLL. From September 2002 to February 2006, 103 patients were enrolled and received at least one dose of alemtuzumab. Median age was 63 years.

Subcutaneous treatment was performed on an outpatient basis in 96 percent of patients and had to be temporarily interrupted in 65 patients due to neutropenia (27 percent), anemia (three percent), thrombocytopenia (eight percent), infections (36 percent), and was stopped early in 65 cases due to insufficient response (43 percent), hematotoxicity (14 percent) and infections (29 percent). The median alemtuzumab dose given was 722 (3-2203) mg.

Toxicity observed during the treatment period was mostly grade 1/2 apart from hematotoxicity. Grade 3/4 neutropenia, thrombocytopenia, and anemia occurred in 56 percent, 57 percent, and 50 percent of patients, respectively. Grade 3/4 non-CMV infection occurred in 29 percent. CMV reactivation was observed in 15 percent total. Grade 3/4 occurred in eight percent of patients. All CMV episodes were successfully treated with anti-CMV therapy, and there was no CMV-related death. Injection site reactions occurred in 34 percent of patients and were grade 1 or 2 except in one patient
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
3. Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week
4. Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007
5. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
6. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
7. Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year
8. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
9. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
10. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
11. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial

Post Your Comments:

(Date:12/17/2009)... Instacare Corp. (OTC Bulletin Board: ISCR) a publicly-traded ... and diagnostics and at home testing products for ... provider of e-health technologies and revolutionary cell phone ... part of the preparation of its Fiscal 2010 ... new Directors and has rejected, as unneeded, multiple ...

(Date:12/17/2009)... Institute today announced that it has acquired e-learning ... life science courseware. These assets, including 155 ... extensive library of training resources. ,, ... training solutions for the pharmaceutical and biotech industry ... terms of the agreement were not disclosed. ,, ...

(Date:12/16/2009)... group of national medical societies launched a multi-state advertising ... and Affordable Care Act, currently under consideration by the ... vote in the coming days. The groups are ... health care bill that is "bad medicine" for patients. ... care system needs reform - but the current Senate ...

Breaking Medicine Technology:Instacare Corp. Board of Directors Sets Growth Plans for 2010 2 Pharmaceutical Institute Acquires E-Learning Assets from GeneEd, Inc. 2 Pharmaceutical Institute Acquires E-Learning Assets from GeneEd, Inc. 3 Physician Groups Oppose Current Senate Health Care Reform Bill 2 JLL Announces Extension of Its Offer to Acquire Patheon and Take Up of Deposited Restricted Voting Shares 47583 1 JLL Announces Extension of Its Offer to Acquire Patheon and Take Up of Deposited Restricted Voting Shares 47583 2 JLL Announces Extension of Its Offer to Acquire Patheon and Take Up of Deposited Restricted Voting Shares 47583 3 Ingenuity and Integromics Offer Integration for Comprehensive Genomics Analysis 47580 1 Ingenuity and Integromics Offer Integration for Comprehensive Genomics Analysis 47580 2 Celsense Inc Receives NIH Grant to Translate Cell Imaging Technology for Clinical Use 12404 1 Celsense Inc Receives NIH Grant to Translate Cell Imaging Technology for Clinical Use 12404 2 Celsense Inc Receives NIH Grant to Translate Cell Imaging Technology for Clinical Use 12404 3

[0] Instacare Corp. Board of Directors Sets Growth Plans for 2010 [0] Pharmaceutical Institute Acquires E-Learning Assets from GeneEd, Inc.[0] Physician Groups Oppose Current Senate Health Care Reform Bill

... Sept. 11 S*BIO Pte Ltd today announced ... for the treatment of myeloproliferative disorders (MPD) and ... by a specific,mutation (V617F) of JAK2 and is ... the bone marrow develops and functions abnormally.,MPD is ...

... Female Health Company,(Amex: FHC ) announced it ... which,implements the USAID | DELIVER PROJECT, for the ... States Agency for International Development,(USAID) programs. For ... international donors,of contraceptives and condoms. The Agency developed ...

Other Medicine Technology:S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies 2 The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units 2

S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units

(Date:12/17/2009)... Physicians Healthcare Management Group, Inc. (Phyhealth) ... it has issued its financial statements for the ... are being posted today on the Pink Sheets ... Management Group, Inc. ,, Physicians Healthcare ... community-based health maintenance organizations (HMOs) that are owned ...

(Date:12/17/2009)... characteristics involved in the exposure of pregnant women to ... standing up or have to lift heavy objects, 63% ... are frequently exposed to some physical risk in their ... especially sensitive to exposure to workplace hazards", M Carmen ... at the Higher Centre for Public Health Research in ...

(Date:12/17/2009)... Stem cells that could one day provide therapeutic ... harvested from the tissue of the umbilical cord, just ... cells to treat some blood disorders, said University of ... version of the Journal of Biomedicine and ... be expanded to greater number, are remarkably stable and ...

(Date:12/17/2009)... Science in Human Resource Development Degree Online , ... ... Open enrollment has begun for Villanova’s newly online HR ... whose busy schedules can’t accommodate a campus-based program. With the ... in March 2010, location is no longer a barrier to ...

(Date:12/17/2009)... -- CareFusion Corporation (NYSE: CFN ) announced ... mini-tender offer by TRC Capital Corporation (TRC) to purchase ... representing approximately 1.8 percent of the shares of common ... is 4.62 percent below the share closing price of ... full trading day prior to the offer. CareFusion also ...

Breaking Medicine News(10 mins):Health News:Phyhealth Issues September 30, 2009 Financial Statements 2 Health News:Almost two-thirds of pregnant women believe they are regularly exposed to physical risk at work 2 Health News:Umbilical cord could be new source of plentiful stem cells, say Pitt researchers 2 Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 2 Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 3 Health News:CareFusion Recommends Rejection of Mini-Tender Offer by TRC Capital 2

[0] Phyhealth Issues September 30, 2009 Financial Statements [0] Almost two-thirds of pregnant women believe they are regularly exposed to physical risk at work [0] Umbilical cord could be new source of plentiful stem cells, say Pitt researchers [0] A World-Class HR Master's Degree Is Now Within Reach – 100% Online [0] CareFusion Recommends Rejection of Mini-Tender Offer by TRC Capital

... track record in supporting clinical trials, most notably in ... Phase I/II clinical testing center at the Walter Reed ... CRM is the premier clinical research organization supporting this ... capabilities, it looked to the National Institute of Allergy ...

... skyrocket over the next five ... according to Millennium Research Group, WALTHAM, Mass., Aug. ... for Women,s Health Imaging Systems 2008 report,the market for ... (MRI) coils, dedicated breast MRI systems, and,breast-specific gamma imaging ...

... Toledo Children,s Hospital and Good Samaritan Hospital, ... NORTH HOLLYWOOD, Calif., Aug. 7 IPC The,Hospitalist ... national hospitalist,physician group practice company, announced today that ... Hospital in Toledo,Ohio and Good Samaritan Hospital in ...

... reported financial results for the three and six months ended June ... ... EON) August 7, 2008 -- Total revenue for the three ... million, respectively, as compared to $496,000 and $999,000, respectively, for the ...

... Aug. 7 Micromet, Inc. (Nasdaq:,MITI), a biopharmaceutical ... for the treatment of cancer, inflammation and,autoimmune diseases, ... and six months ended June 30, 2008., ... and MedImmune presented a clinical update for the,BiTE(R) ...

... to $9.6 million from $4.9 million -, LISLE, ... or the "Company") (NASDAQ: SXCI , TSX: SXC), ... ended June 30, 2008. Financial,references are in U.S. dollars ... National Medical Health Card Systems,Inc. ("NMHC") on April 30, ...

Clinical Research Management gets contract for trials of therapeutics against infectious diseases Adjunct Breast Imaging Market to Increase by Almost 28% per Year Through 2013 IPC The Hospitalist Company Enters Ohio and Pennsylvania Markets Therapeutic DNA Vaccine Company Inovio Biomedical Reports Second Quarter 2008 Financial Results Micromet, Inc. Reports Second Quarter 2008 Financial Results SXC Health Solutions announces second quarter financial results

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

Medicine Products:

Alanine Aminotransferase, Serum or Plasma Al, Plasma AFP-L3%AFP (Tumor Marker)

Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with Hig...(atients in this group could receive all ...),Health